Macroaxis LLC’s Post

$AGLE - Ready to toss Aeglea Bio? Next financial report is on 9th of May 2024.: About 98.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.35. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aeglea Bio Therapeutics recorded a loss per share of 74.15. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 8th of September 2023. https://lnkd.in/gPh3T6R9 #stocks #stocktwits #thematic_portfolio

Perspective Therapeutics ( $CATX ) current daily volatility is 8.05%, with beta of 1.17 and alpha of 1.19 over NYSE Composite: The company currently falls under 'Small-Cap' category with a current market capitalization of 161.33 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Perspective Therapeutics's market, we take the total number of its shares issued and multiply it by Perspective Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Perspective Therapeutics preserves 64.44 m of net asset. Perspective Therapeutics is trading at 0.4791, which is -15.95 percent decrease. Today lowest is 0.48. https://lnkd.in/gFCgaGir #hotstocks #investing #trading

$AGLE - Is Aeglea Bio a good shorter-term buy? Next financial report is on 9th of May 2024.: About 98.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.35. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aeglea Bio Therapeutics recorded a loss per share of 74.15. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 8th of September 2023. #stocks #stocktwits #thematic_portfolio

$VTGN - Next financial report expected on 26th of June 2024.: About 63.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.01. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. VistaGen Therapeutics recorded a loss per share of 2.96. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 7th of June 2023. https://lnkd.in/gQ6_iaf4 #stocks #stocktwits #thematic_portfolio

Alembic Pharma is making waves as one of the breakout stocks! 🌐 ✨ Key Stats: 💰 Market Capitalization: ₹17,308 Crores 📊 Stock P/E Ratio: 32.6 🏭 Industry P/E: 41.88 💵 Earnings Per Share (EPS): ₹27.05 📘 Book Value: ₹227 🚀 The market capitalization of ₹17,308 Crores reflects strong investor confidence, and with a Stock P/E Ratio of 32.6, Alembic Pharma is showing promising growth potential. 📈 Compared to the industry P/E of 41.88, Alembic Pharma seems to be an attractive investment opportunity, suggesting there might be room for further appreciation in stock value. 💡 Earnings Per Share (EPS) at ₹27.05 showcases the company's profitability, and the Book Value of ₹227 highlights the intrinsic value for shareholders. 🔍 Dive into the details and consider adding Alembic Pharma to your watchlist! 📈💼 #StockMarket #Investing #AlembicPharma #BreakoutStocks #Finance Note - All Suggestions only for educational purposes.

Discover the latest trends in early-stage biopharma investments with our comprehensive report, "Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective." From Series A financing peaks to the dominance of biologicals and the resurgence of biopharma IPOs, get all the insights you need to stay ahead in the market. 📥 Download your free copy today! 👉 https://ter.li/wtpcs3 #Biopharma #InvestmentTrends #SeriesAFinancing #BeaconData #MarketInsights #InvestmentStrategy

Bespoke posts on X: These are the 38 stocks in the S&P 1500 that are up 100%+ on the year with six trading days left. Who had Abercrombie & Fitch $ANF on their list of top performers at the start of the year? It's currently up more than any other stock in the index with a YTD gain of nearly 300%. Link: https://lnkd.in/g5iqGBmd My take: If you think ANF had impressive gains this year, come into my biotech universe and check out gains in Soleno Therapeutics (SLNE), Gyre Therapeutics (GYRE), EyePoint Pharmaceuticals (EYPT), Viking Therapeutics (VKTX) and a bunch more biotechs that doubled and quadrupled from their bottom and were great to trade this year. Anyway, have fun looking at the list below, good to know in case one of your relatives annoys you this holiday season about how much money they made in the stock market. 😁

Check this portfolio in April 2024: Cardinal Health( $CAH ), Hashicorp( $HCP ), General Dynamics( $GD ), Omega Therapeutics( $OMGA ), Chevron Corp( $CVX ), Prologis( $PLD ), Principal Financial( $PFG ), Gannett( $GCI ) and Equifax( $EFX ) https://lnkd.in/gBTVcvNC #stocks #stocktwits #thematic_portfolio

$MOLA - 15 for 1 Split can cause some disturbance for MOLECULIN BIOTECH: About 17.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.73. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MOLECULIN BIOTECH recorded a loss per share of 1.31. The entity had not issued any dividends in recent years. The firm had 15:1 split on the 2nd of January 2024. https://lnkd.in/gZ23-XGb #stocks #stocktwits #thematic_portfolio

Thoughts on this? >> Biotech industry flirts with XBI milestone as it surpasses $100 >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #biotech #pharmaceutical #productmarketing